Rheumatology-related drug safety, approvals, and what’s in the pipeline.
A Short History of Rheumatoid Arthritis Therapeutics
Or, why I chose to become a rheumatologist
Opening a New Therapeutic Window for Rheumatoid Arthritis
New targets in rheumatoid arthritis: SYK, JAK, BTK
Drug Updates: Apremilast, Belimumab, and More
Information on new approvals and medication safety
Drug Updates
Information on New Approvals and Medication Safety
Meet the Model Biologics Policy
At its February meeting, the ACR board of directors approved the Model Biologics Policy, which will be used when discussing guidelines and patients’ quality of treatment with health insurance companies.
Integrating Immunology and Biologics into Clinical Practice
With the rapid expansion of new classes of medications, clinical practice has changed dramatically, and rheumatology health professionals must have a fundamental knowledge of immunology and the mechanisms of action of the biologic agents that have emerged with this expansion. Familiarity with the predrug screening recommended for biologic agents and the appropriate safety and disease monitoring necessary when a person uses these products is essential for the best patient outcomes. Additionally, being able to obtain drug plan authorization for use of biologics and being able to educate patients and their families or support team members about the financial considerations of these drugs helps to ensure best rheumatology practice.
Cochrane Launches Journal Club with RA Article
Overview of studies on biologic use kicks off monthly literature review feature
Drug Risk Versus Benefit
Perceptions from the FDA, physicians, and patients
Biologic Logic: Making Sense of Current Therapies for Rheumatic Diseases
Continuing the ARHP 2009 Audioconference/Webcast series, Daniel F. Battafarano, DO, FACP, FACR, will discuss the use of biologic therapy in the treatment of rheumatology patients on February 10 from noon to 1:00 pm ET. During the session, Dr. Battafarano will review basic immunology, inflammation, and relevant cytokines for common rheumatic diseases. In addition, he will describe the current biologic therapies and their relationship to rheumatic disease outcomes, and identify future biologic strategies for therapy.